

Patient-Centered Care in Genomics & Precision Health

Shivani Nazareth


- Board-certified Genetic Counselor
- VP of Digital Health Strategy at Myriad Genetics

Disclosures


- Employee of Myriad Genetics
- Advisor to Juniper Genomics



Preventive Health Begins with Insights



Unlocking Genetic Health Over One's Lifespan




The Life-Saving Secrets in Your Baby's DNA



“Genomics is the tip of the spear for preventive care; it’s really the first in a series of things that we need to bring in order to preserve our health — multi omics, proteomics, transcriptomics, wearables — all of the exciting things that we have heard about that will keep us well instead of simply treating us when we’re sick.”

Personal AI Navigator

Anticipatory guidance for health decisions utilizing the data



Hippocratic AI
— Do No Harm —

University Hospitals and Hippocratic AI Collaborate to Advance Patient Outcomes Through Safe, Patient-Facing AI

September 10, 2025

By [Ansley Kelm](#)

Share



Cleveland, Ohio & Palo Alto, Calif. – University Hospitals, a nationally recognized academic health system named by U.S. News & World Report to its Best Hospitals list, an achievement it has made 27 years in a row and Hippocratic AI, the global leader and pioneer in generative AI healthcare agents, today announced a strategic collaboration to transform how patients are supported across the care journey. The

My personal story

HealthAffairs

NARRATIVE MATTERS



DOI: 10.1377/HLTHAFF.2021.00967

To Uncover My Mother's Genetic Disorder, I Had To Lead The Way

A genetic counselor uses her own resources to identify the root cause of her mother's changing personality.

BY SHIVANI NAZARETH

Conversations
ingly repetitive,
ulate home was
useless items:
unread magazin
tles strewn abo
clothing marke
be a guest bedr
come uninteres
the context of t
this behavior h
if not praised.
mental health
"Nothing is w
sisted, while re
food from her 1

In truth, my n
woman of her o
like, easy to lov
I did not know
both of these fe
go for long stre
but we also sha
about the sear
world. She coul
often cooking
whim, but also
of anger, she w
life. From a you
she struggled w
migrant family
vocabulary to
and therapy lec
sentment to to
had a formal di
During visits
mother someti
with caution, "



"...I am coming to terms with my mother's future, and potentially my own. I have a 50% chance of inheriting the same disease-causing variant, for which there is currently no treatment."

Using AI to navigate decisions

HEALTH AND MEDICINE

The Neuroscience of Decision-Making: Why We Choose What We Do

Editors of ScienceNewsToday · August 8, 2025

“At its core, decision-making is not a single act, but a process—a choreography involving sensory perception, emotional valuation, memory recall, and risk assessment.”

OpenEvidence has signed content agreements with [JAMA](#) and [The New England Journal of Medicine](#).

OpenEvidence  Share  New Question 

What is the latest treatment for patients with c9orf72 mutations?

▼ Finished thinking

The latest treatments for patients with C9orf72 mutations in ALS/FTD are focused on targeted molecular therapies, particularly antisense oligonucleotides (ASOs), RNA-targeting CRISPR systems, small molecule inhibitors, and gene-editing approaches, with most still in preclinical or early clinical development.

ASOs are designed to selectively suppress mutant C9orf72 transcripts and reduce dipeptide repeat proteins. Early clinical data show that intrathecal delivery of opt ASOs can significantly lower pathogenic markers in patients, with improved toler and efficacy demonstrated in both patient-derived cells and animal models.^[1-3]

RNA-targeting CRISPR systems, such as Cas13d/CasRx, have shown the ability to reduce both sense and antisense repeat RNAs and their associated toxic protein in preclinical models. These systems offer improved specificity and have demonstrated neuroprotection and reversal of disease phenotypes in patient-derived neurons and transgenic mice.^[4-6]

OpenEvidence has signed content agreements with [JAMA](#) and [The New England Journal of Medicine](#).

OpenEvidence  Share  New Question 

Please summarize the latest published clinical trial results for antisense oligonucleotide therapies targeting C9orf72, including their safety, efficacy, and current trial status.

▼ Finished thinking

Recent clinical trial results for antisense oligonucleotide (ASO) therapies targeting C9orf72 mutations in ALS/FTD show robust molecular target engagement but have not demonstrated clinical efficacy, and safety concerns remain.

The most advanced clinical trial involved BII078, an ASO targeting C9orf72 repeat transcripts. While BII078 achieved widespread CNS distribution and reduced dipeptide repeat proteins (DPRs) in cerebrospinal fluid, it did not alter key neuropathological features such as phosphorylated TDP-43 or provide clinical benefit. Notably, treatment was associated with sustained increases in inflammatory biomarkers, raising concerns about safety and tolerability. The trial was discontinued due to lack of efficacy and safety signals.^[1-3]

Thank you

DEPT. OF FIRST PRINCIPLES

THE ART OF DECISION-MAKING

Your life choices aren't just about what you want to do; they're about who you want to be.



By Joshua Rothman

January 14, 2019



Your life choices are shadowed by ignorance: you choose to be a parent without knowing what being a parent will be like. Illustration by Anna Parini

THE NEW YORKER

“For Tolstoy, the tendency of big decisions to make themselves was one of the great mysteries of existence. It suggested that the stories we tell about our lives are inadequate to their real complexity.”

“We’re hardly more advanced than the ancient Persians, who, Herodotus says, made big decisions by discussing them twice: once while drunk, once while sober.”